Celgene invests significant resources into creating disease altering therapies for cancer and other serious immune-inflammatory conditions. Currently, the Celgene pipeline consists of more than 25 unique compounds addressing more than 30 disease areas.
There are hundreds of clinical studies being conducted around the world utilizing our products.
The products represented as in development and found in the product pipeline are intended for investors and members of the media to provide general information on Celgene. This information is not represented to be a complete description and is subject to change without notice. Celgene Corporation may from time to time update this information but does not warrant that will take place at any particular time nor assume any obligation to update this information.